<?xml version="1.0" ?>
<text author="Jose-Manuel delMoral-Sanchez, Isabel Gonzalez-Alvarez, Marta Gonzalez-Alvarez, Andres Navarro, Marival Bermejo" dateCollected="2019-11-03" id="autogum_academic_doc456" shortTile="classification-essential" sourceURL="https://www.mdpi.com/1999-4923/11/11/567/htm" speakerCount="0" speakerList="none" title="Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System" type="academic">
<head>
<s>
1	CD	1
.	.	.
</s>
<s>
Introduction	NN	introduction
</s>
</head>
<p>
<s>
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
paper	NN	paper
was	VBD	be
using	VBG	use
the	DT	the
Essential	NNP	Essential
Medicines	NNPS	Medicines
List	NNP	list
for	IN	for
children	NNS	child
by	IN	by
the	DT	the
World	NNP	World
Health	NNP	Health
Organization	NNP	Organization
(	-LRB-	(
WHO	WP	who
)	-RRB-	)
to	TO	to
create	VB	create
a	DT	a
provisional	JJ	provisional
pediatric	JJ	pediatric
biopharmaceutics	NN	biopharmaceutics
classification	NN	classification
system	NN	system
(	-LRB-	(
pBCS	NNP	pBCS
)	-RRB-	)
for	IN	for
oral	JJ	oral
drugs	NNS	drug
and	CC	and
to	TO	to
compare	VB	compare
our	PRP$	our
results	NNS	result
with	IN	with
the	DT	the
BCS	NNP	BCS
for	IN	for
adults	NNS	adult
(	-LRB-	(
aBCS	NNP	aBCS
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s>
Since	IN	since
2007	CD	@card@
,	,	,
the	DT	the
WHO	WP	who
has	VBZ	have
provided	VBN	provide
the	DT	the
WHO	WP	who
Model	NNP	Model
List	NNP	list
of	IN	of
Essential	NNP	Essential
Medicines	NNPS	Medicines
for	IN	for
Children	NNPS	Children
;	:	;
a	DT	a
core	JJ	core
drug	NN	drug
list	NN	list
for	IN	for
a	DT	a
basic	JJ	basic
health-care	JJ	health-care
system	NN	system
.	.	.
</s>
<s>
This	DT	this
resource	NN	resource
list	NN	list
considers	VBZ	consider
the	DT	the
safest	JJS	safe
,	,	,
efficacious	JJ	efficacious
and	CC	and
cost-effective	JJ	cost-effective
drugs	NNS	drug
for	IN	for
priority	NN	priority
pathologies	NNS	pathology
in	IN	in
pediatrics	NN	pediatrics
up	RP	up
to	TO	to
12	CD	@card@
years	NNS	year
old	JJ	old
.	.	.
</s>
<s>
All	DT	all
immediate	JJ	immediate
release	NN	release
oral	JJ	oral
drugs	NNS	drug
from	IN	from
the	DT	the
sixth	JJ	sixth
edition	NN	edition
of	IN	of
this	DT	this
list	NN	list
were	VBD	be
selected	VBN	select
for	IN	for
this	DT	this
work	NN	work
.	.	.
</s>
</p>
<p>
<s>
The	DT	the
need	NN	need
for	IN	for
and	CC	and
importance	NN	importance
of	IN	of
developing	VBG	develop
appropriate	JJ	appropriate
,	,	,
safe	JJ	safe
and	CC	and
effective	JJ	effective
medicines	NNS	medicine
for	IN	for
pediatrics	NN	pediatrics
have	VBP	have
now	RB	now
been	VBN	be
recognized	VBN	recognize
.	.	.
</s>
<s>
Pediatrics	NN	Pediatrics
have	VBP	have
long	RB	long
been	VBN	be
considered	VBN	consider
as	IN	as
a	DT	a
therapeutically	RB	therapeutically
disregarded	VBN	disregarded
group	NN	group
.	.	.
</s>
<s>
This	DT	this
fact	NN	fact
lies	VBZ	lie
in	IN	in
the	DT	the
therapeutic	JJ	therapeutic
gap	NN	gap
that	WDT	that
originates	VBZ	originate
from	IN	from
formulation	NN	formulation
development	NN	development
(	-LRB-	(
mainly	RB	mainly
focused	VBN	focus
on	IN	on
adults	NNS	adult
)	-RRB-	)
,	,	,
low	JJ	low
availability	NN	availability
of	IN	of
commercial	JJ	commercial
pediatric	JJ	pediatric
drugs	NNS	drug
for	IN	for
pediatric	JJ	pediatric
use	NN	use
and	CC	and
physiological	JJ	physiological
and	CC	and
anatomical	JJ	anatomical
differences	NNS	difference
relative	JJ	relative
to	TO	to
the	DT	the
adult	JJ	adult
population	NN	population
.	.	.
</s>
</p>
<p>
<s>
In	IN	in
younger	JJR	young
pediatrics	NN	pediatrics
,	,	,
neonates	NNS	neonate
and	CC	and
infants	NNS	infant
,	,	,
the	DT	the
therapeutic-risk	JJ	therapeutic-risk
benefits	NNS	benefit
associated	VBN	associate
with	IN	with
drug	NN	drug
treatment	NN	treatment
may	MD	may
be	VB	be
different	JJ	different
from	IN	from
those	DT	those
in	IN	in
adults	NNS	adult
.	.	.
</s>
<s>
Developmental	JJ	Developmental
physiological	JJ	physiological
differences	NNS	difference
(	-LRB-	(
as	IN	as
the	DT	the
composition	NN	composition
of	IN	of
gastrointestinal	JJ	gastrointestinal
fluids	NNS	fluid
and	CC	and
the	DT	the
presence	NN	presence
or	CC	or
activity	NN	activity
of	IN	of
intestinal	NN	intestinal
drug	NN	drug
metabolizing	NN	metabolize
enzymes	NNS	enzyme
and	CC	and
efflux	NN	efflux
transporters	NNS	transporter
)	-RRB-	)
can	MD	can
markedly	RB	markedly
alter	VB	alter
the	DT	the
bioavailability	NN	bioavailability
of	IN	of
drugs	NNS	drug
.	.	.
</s>
<s>
Age-related	VBN	Age-related
changes	NNS	change
in	IN	in
the	DT	the
characteristics	NNS	characteristic
of	IN	of
luminal	JJ	luminal
fluids	NNS	fluid
such	JJ	such
as	IN	as
pH	NN	pH
may	MD	may
lead	VB	lead
to	TO	to
changes	NNS	change
in	IN	in
drug	NN	drug
solubility	NN	solubility
and	CC	and
,	,	,
therefore	RB	therefore
,	,	,
in	IN	in
absorption	NN	absorption
since	IN	since
only	RB	only
the	DT	the
dissolved	VBN	dissolve
drug	NN	drug
would	MD	would
be	VB	be
available	JJ	available
for	IN	for
absorption	NN	absorption
.	.	.
</s>
<s>
Since	IN	since
fluctuations	NNS	fluctuation
in	IN	in
pH	NN	pH
may	MD	may
influence	VB	influence
ionizable	JJ	ionizable
drugs	NNS	drug
and	CC	and
the	DT	the
relative	JJ	relative
amount	NN	amount
of	IN	of
unionized	JJ	unionized
available	JJ	available
drug	NN	drug
,	,	,
there	EX	there
could	MD	could
be	VB	be
changes	NNS	change
in	IN	in
absorption	NN	absorption
during	IN	during
maturation	NN	maturation
.	.	.
</s>
<s>
The	DT	the
gastric	JJ	gastric
pH	NN	pH
of	IN	of
the	DT	the
newborn	NN	newborn
is	VBZ	be
approximately	RB	approximately
neutral	JJ	neutral
,	,	,
and	CC	and
within	IN	within
the	DT	the
first	JJ	first
48	CD	@card@
h	NN	h
of	IN	of
life	NN	life
,	,	,
the	DT	the
gastrointestinal	JJS	gastrointestinal
pH	NN	pH
decreases	VBZ	decrease
to	TO	to
adult	JJ	adult
values	NNS	value
and	CC	and
then	RB	then
for	IN	for
the	DT	the
first	JJ	first
month	NN	month
increases	NNS	increase
back	RB	back
to	TO	to
values	NNS	value
close	JJ	close
to	TO	to
neutrality	NN	neutrality
.	.	.
</s>
<s>
After	IN	after
the	DT	the
first	JJ	first
month	NN	month
,	,	,
gastric	NN	gastric
pH	NN	pH
decreases	VBZ	decrease
progressively	RB	progressively
to	TO	to
reach	VB	reach
similar	JJ	similar
values	NNS	value
as	IN	as
in	IN	in
adults	NNS	adult
by	IN	by
two	CD	two
years	NNS	year
of	IN	of
age	NN	age
.	.	.
</s>
</p>
<p>
<s>
On	IN	on
the	DT	the
other	JJ	other
hand	NN	hand
,	,	,
another	DT	another
determinant	NN	determinant
of	IN	of
bioavailability	NN	bioavailability
is	VBZ	be
ontogenic	JJ	ontogenic
changes	NNS	change
in	IN	in
the	DT	the
expression	NN	expression
of	IN	of
drug	NN	drug
metabolizing	NN	metabolize
enzymes	NNS	enzyme
and	CC	and
transporters	NNS	transporter
,	,	,
which	WDT	which
would	MD	would
mark	VB	mark
the	DT	the
first	JJ	first
pass	NN	pass
effect	NN	effect
and	CC	and
consequently	RB	consequently
would	MD	would
change	VB	change
the	DT	the
oral	JJ	oral
absorbed	VBN	absorbed
fraction	NN	fraction
.	.	.
</s>
<s>
For	IN	for
example	NN	example
,	,	,
the	DT	the
CYP3A4	NNP	CYP3A4
isoenzyme	NN	isoenzyme
increases	VBZ	increase
expression	NN	expression
and	CC	and
activity	NN	activity
with	IN	with
age	NN	age
.	.	.
</s>
<s>
CYP3A4	NNP	CYP3A4
is	VBZ	be
practically	RB	practically
undetectable	JJ	undetectable
in	IN	in
neonates	NNS	neonate
,	,	,
and	CC	and
its	PRP$	its
expression	NN	expression
increases	VBZ	increase
with	IN	with
age	NN	age
,	,	,
reaching	VBG	reach
a	DT	a
maximum	JJ	maximum
level	NN	level
at	IN	at
two	CD	two
years	NNS	year
of	IN	of
age	NN	age
.	.	.
</s>
<s>
Likewise	RB	likewise
,	,	,
in	IN	in
these	DT	these
age	NN	age
groups	NNS	group
,	,	,
there	EX	there
is	VBZ	be
immature	JJ	immature
intestinal	JJ	intestinal
activity	NN	activity
of	IN	of
alkaline	JJ	alkaline
phosphatase	NN	phosphatase
,	,	,
glucuronidation	NN	glucuronidation
enzymes	NNS	enzyme
and	CC	and
carboxylesterase-2	NN	carboxylesterase-2
.	.	.
</s>
<s>
Conversely	RB	Conversely
,	,	,
there	EX	there
are	VBP	be
no	DT	no
differences	NNS	difference
in	IN	in
p-glycoprotein	NN	p-glycoprotein
expression	NN	expression
,	,	,
the	DT	the
most	RBS	most
studied	VBN	study
intestinal	JJ	intestinal
efflux	NN	efflux
transporter	NN	transporter
from	IN	from
the	DT	the
earliest	JJS	early
stages	NNS	stage
of	IN	of
life	NN	life
to	TO	to
adults	NNS	adult
.	.	.
</s>
</p>
<p>
<s>
Many	JJ	Many
drugs	NNS	drug
are	VBP	be
formulated	VBN	formulate
as	IN	as
pharmaceutical	JJ	pharmaceutical
forms	NNS	form
that	WDT	that
are	VBP	be
often	RB	often
not	RB	not
appropriate	JJ	appropriate
for	IN	for
pediatrics	NN	pediatrics
,	,	,
such	JJ	such
as	IN	as
tablets	NNS	tablet
or	CC	or
capsules	NNS	capsule
.	.	.
</s>
<s>
Children	NNS	Children
need	VBP	need
different	JJ	different
oral	JJ	oral
dosage	NN	dosage
formulations	NNS	formulation
from	IN	from
adults	NNS	adult
mainly	RB	mainly
due	JJ	due
to	TO	to
their	PRP$	their
developmental	JJ	developmental
capabilities	NNS	capability
in	IN	in
swallowing	VBG	swallow
ability	NN	ability
,	,	,
palatability	NN	palatability
and	CC	and
dosage	NN	dosage
requirements	NNS	requirement
.	.	.
</s>
<s>
Especially	RB	especially
in	IN	in
pediatrics	NN	pediatrics
,	,	,
palatability	NN	palatability
is	VBZ	be
closely	RB	closely
related	VBN	relate
to	TO	to
acceptance	NN	acceptance
and	CC	and
adherence	NN	adherence
.	.	.
</s>
<s>
Consequently	RB	consequently
,	,	,
bitterness	NN	bitterness
,	,	,
trigeminal	JJ	trigeminal
irritation	NN	irritation
and	CC	and
perceptible	JJ	perceptible
malodors	NNS	malodor
must	MD	must
be	VB	be
minimized	VBN	minimize
.	.	.
</s>
</p>
<p>
<s>
The	DT	the
increasing	VBG	increase
need	NN	need
for	IN	for
age-related	JJ	age-related
medicines	NNS	medicine
in	IN	in
pediatrics	NN	pediatrics
could	MD	could
be	VB	be
met	VBN	meet
by	IN	by
extemporaneous	JJ	extemporaneous
formulations	NNS	formulation
.	.	.
</s>
<s>
The	DT	the
compounding	NN	compound
of	IN	of
an	DT	an
extemporaneous	JJ	extemporaneous
formula	NN	formula
is	VBZ	be
not	RB	not
allowed	VBN	allow
if	IN	if
an	DT	an
authorized	VBN	authorize
commercial	JJ	commercial
pharmaceutical	JJ	pharmaceutical
product	NN	product
(	-LRB-	(
adequate	JJ	adequate
for	IN	for
a	DT	a
particular	JJ	particular
age	NN	age
group	NN	group
)	-RRB-	)
exists	VBZ	exist
,	,	,
but	CC	but
the	DT	the
reality	NN	reality
in	IN	in
the	DT	the
clinical	JJ	clinical
setting	NN	set
is	VBZ	be
that	IN	that
for	IN	for
some	DT	some
age	NN	age
groups	NNS	group
,	,	,
that	DT	that
is	VBZ	be
not	RB	not
the	DT	the
case	NN	case
,	,	,
while	IN	while
extemporaneous	JJ	extemporaneous
formulation	NN	formulation
is	VBZ	be
still	RB	still
used	VBN	use
as	IN	as
the	DT	the
only	JJ	only
alternative	NN	alternative
to	TO	to
the	DT	the
therapeutic	JJ	therapeutic
need	NN	need
.	.	.
</s>
<s>
Although	IN	although
solid	JJ	solid
products	NNS	product
have	VBP	have
higher	JJR	high
stability	NN	stability
than	IN	than
liquid	NN	liquid
formulations	NNS	formulation
,	,	,
this	DT	this
practice	NN	practice
can	MD	can
solve	VB	solve
the	DT	the
problem	NN	problem
of	IN	of
swallowing	VBG	swallow
capability	NN	capability
and	CC	and
dose	NN	dose
adjustments	NNS	adjustment
,	,	,
but	CC	but
these	DT	these
manufactured	VBN	manufacture
preparations	NNS	preparation
can	MD	can
be	VB	be
a	DT	a
risk	NN	risk
to	TO	to
safety	NN	safety
,	,	,
efficacy	NN	efficacy
and	CC	and
quality	NN	quality
,	,	,
because	IN	because
there	EX	there
is	VBZ	be
little	RB	little
or	CC	or
no	DT	no
information	NN	information
for	IN	for
compatibility	NN	compatibility
between	IN	between
the	DT	the
original	JJ	original
medicine	NN	medicine
and	CC	and
additional	JJ	additional
excipients	NNS	excipient
or	CC	or
their	PRP$	their
effect	NN	effect
in	IN	in
children	NNS	child
.	.	.
</s>
<s>
The	DT	the
excipients	NNS	excipient
used	VBN	use
in	IN	in
formulations	NNS	formulation
designed	VBN	design
for	IN	for
children	NNS	child
should	MD	should
be	VB	be
appropriate	JJ	appropriate
for	IN	for
each	DT	each
age	NN	age
group	NN	group
because	IN	because
,	,	,
as	IN	as
is	VBZ	be
known	VBN	know
,	,	,
these	DT	these
are	VBP	be
not	RB	not
inert	JJ	inert
substances	NNS	substance
and	CC	and
cannot	MD	can
be	VB	be
supposed	VBN	suppose
to	TO	to
have	VB	have
the	DT	the
same	JJ	same
effects	NNS	effect
in	IN	in
pediatrics	NN	pediatrics
as	IN	as
in	IN	in
adults	NNS	adult
.	.	.
</s>
<s>
The	DT	the
most	RBS	most
common	JJ	common
example	NN	example
is	VBZ	be
early	JJ	early
stage	NN	stage
children	NNS	child
who	WP	who
are	VBP	be
not	RB	not
able	JJ	able
to	TO	to
metabolize	VB	metabolize
or	CC	or
eliminate	VB	eliminate
them	PRP	them
as	IN	as
adults	NNS	adult
.	.	.
</s>
<s>
The	DT	the
ideal	JJ	ideal
situation	NN	situation
in	IN	in
the	DT	the
development	NN	development
of	IN	of
pediatric	JJ	pediatric
formulations	NNS	formulation
is	VBZ	be
the	DT	the
minimal	JJ	minimal
use	NN	use
of	IN	of
added	VBN	add
excipients	NNS	excipient
,	,	,
both	DT	both
in	IN	in
number	NN	number
and	CC	and
quantity	NN	quantity
.	.	.
</s>
</p>
</text>
